跳至主要内容
临床试验/NL-OMON44196
NL-OMON44196已完成不适用

A randomized, 2-part, placebo controlled phase 1 study to evaluate safety, tolerability, pharmacokinetics and immunogenicity following single ascending doses (Part 1) and multiple ascending doses (Part 2) of GBR 830 in adult healthy subjects - GBR 830 SAD and MAD study

Glenmark Pharmaceuticals SA0 个研究点目标入组 32 人开始时间: 待定最近更新:

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
32

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 64(—)

入选标准

  • - healthy volunteers
  • - 18 - 65 years, inclusive
  • - BMI: 18.5 - 32.0 kg/m2, inclusive

排除标准

  • Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 3 months before the start of this study. Subjects with a history of donating 1 unit of blood (450 mL) blood in the 3 months prior to IP administration or who intend to donate within 3 months of their last scheduled study visit.

研究者

发起方
Glenmark Pharmaceuticals SA

相似试验